Detalhe da pesquisa
1.
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
Prostate
; 84(3): 292-302, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37964482
2.
Symptom Clusters in Patients With Advanced Cancer: A Prospective Longitudinal Cohort Study to Examine Their Stability and Prognostic Significance.
Oncologist
; 29(1): e152-e163, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37536276
3.
Treatment of renal cell carcinoma: Current status and future directions.
CA Cancer J Clin
; 67(6): 507-524, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961310
4.
Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide.
Prostate
; 83(11): 1028-1034, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37113064
5.
Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer.
Prostate
; 83(9): 879-885, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36959766
6.
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Prostate
; 83(3): 227-236, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36382533
7.
Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
Cancer
; 129(24): 3884-3893, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37565840
8.
Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study.
Oncologist
; 28(9): e737-e747, 2023 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37014097
9.
Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study.
Oncologist
; 28(9): 780-789, 2023 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37014080
10.
Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
Oncologist
; 28(10): 894-900, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37315114
11.
Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab.
Oncologist
; 28(3): 276-e158, 2023 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36210487
12.
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Cancer
; 128(6): 1194-1205, 2022 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34882781
13.
Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer.
Oncologist
; 27(3): 220-227, 2022 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35274720
14.
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race.
Oncologist
; 27(10): e815-e818, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36036607
15.
Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma.
Curr Treat Options Oncol
; 22(2): 15, 2021 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33438115
16.
Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.
Oncologist
; 25(4): 327-333, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32297439
17.
Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or .
Cancer
; 125(11): 1777-1788, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30933324
18.
Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
Invest New Drugs
; 37(2): 331-337, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30402678
19.
Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer.
Invest New Drugs
; 37(6): 1231-1238, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31231785
20.
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Cancer
; 124(10): 2115-2124, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29517810